Bionano Genomics (BNGO) Projected to Post Quarterly Earnings on Monday

Bionano Genomics (NASDAQ:BNGO) is anticipated to issue its Q4 2025 results before the market opens on Monday, March 9th. Analysts expect the company to announce earnings of ($0.81) per share and revenue of $7.88 million for the quarter. Investors may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Thursday, March 12, 2026 at 4:00 PM ET.

Bionano Genomics Stock Down 0.9%

Shares of Bionano Genomics stock opened at $1.12 on Friday. The company has a quick ratio of 1.82, a current ratio of 2.12 and a debt-to-equity ratio of 0.07. Bionano Genomics has a 52-week low of $1.06 and a 52-week high of $5.50. The company has a market capitalization of $11.40 million, a P/E ratio of -0.24 and a beta of 1.69. The company has a 50 day moving average of $1.34 and a 200 day moving average of $1.89.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on BNGO shares. HC Wainwright reissued a “buy” rating and issued a $7.00 price target (down from $11.00) on shares of Bionano Genomics in a research report on Monday, November 24th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Bionano Genomics in a report on Monday, December 29th. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Bionano Genomics currently has an average rating of “Hold” and an average price target of $5.50.

Institutional Trading of Bionano Genomics

A number of hedge funds have recently made changes to their positions in the company. DRW Securities LLC purchased a new stake in Bionano Genomics during the 4th quarter worth $258,000. Geode Capital Management LLC grew its stake in Bionano Genomics by 148.8% during the 4th quarter. Geode Capital Management LLC now owns 66,766 shares of the company’s stock valued at $102,000 after purchasing an additional 39,928 shares in the last quarter. Renaissance Technologies LLC acquired a new stake in Bionano Genomics during the 4th quarter valued at approximately $57,000. Jane Street Group LLC purchased a new stake in Bionano Genomics during the 4th quarter worth approximately $34,000. Finally, Carret Asset Management LLC increased its holdings in Bionano Genomics by 76.4% during the 4th quarter. Carret Asset Management LLC now owns 44,100 shares of the company’s stock worth $67,000 after purchasing an additional 19,100 shares during the last quarter. Hedge funds and other institutional investors own 11.35% of the company’s stock.

About Bionano Genomics

Bionano Genomics, Inc (NASDAQ: BNGO) develops and commercializes high‐resolution genome analysis tools designed to map structural variants and large‐scale genomic rearrangements. At the core of its technology is the Saphyr® optical genome mapping system, which uses nanochannel arrays to linearize megabase‐length DNA molecules, proprietary fluorescent labeling reagents to highlight specific sequence motifs, and advanced image processing software to detect structural changes with high sensitivity.